Zealand Pharma delivers best result ever
Following a European approval of a diabetes drug, the Danish company Zealand Pharma has secured a better financial result than ever before, however, there is still some uncertainty about revenue in 2013.
by Leonora Beck
2012 was a crucial year for Zealand Pharma, which can be seen in both the top and bottom line of the company’s recently-published full-year results. The biotech company presented turnover of 224 million kroner (EUR 30 million) and net results of 36 million kroner (EUR 5 million) in 2012 – the best financial result in the history of the company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Zealand will go it alone with heart medicine
For abonnenter
